Motif Bio plc

Mofit BioSciencesMotif Bio plc (LSE: MTFB) is developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.  Motif has a lead antibiotic candidate, iclaprim, and MTF-001, a preclinical program to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).  Discussions and negotiations with academic institutions are under way to build a portfolio of antibiotic candidates through licensing.  It is anticipated that Motif’s lead antibiotic candidate could be ready for commercialization as early as 2018.

Motif has recruited a highly experienced team of drug discovery scientists – former senior executives at Merck, Schering Plough, Wyeth, GlaxoSmithKline, and Bayer - in medicinal and computational chemistry, biology, toxicology, pharmacology, and clinical development to capitalize on the growing trend of pharmaceutical companies to outsource drug discovery to small specialized players.

Motif


Management

Graham Lumsden- Chief Executive Officer
Robert Bertoldi- Chief Financial Officer, VP Business Development
David Huang M.D., Ph.D., JD- Chief Medical Officer
Matthew J. Wyvratt, Ph.D. - Senior Vice President, Drug Discovery
Jerauld S. Skotnicki, Ph.D. - Executive Director, Medicinal Chemistry
Mark L. Greenlee, Ph.D. - Executive Director, Medicinal Chemistry

Board of Directors

Richard C.E. Morgan - (Chairman) Chief Executive Officer, Amphion Innovations
Zaki Hosny- (Deputy Chairman)
Jon Gold - Senior Financial Analyst, Federated Investments
Dr. Mary Lake Polan - Board of Directors, Wyeth Corporation, formally Professor and Chair emeritus, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Dr. John Stakes - Director of Specialty Care Development, Harvard Medical School and Massachusetts General Hospital
Bruce Williams - Biotechnology Industry Consultant, formally held senior marketing positions at Celgene Corp., and Ortho Biotech, a Johnson & Johnson company


Website

 

Top of page